US20080119657A1 - Phenyltetrazole compounds - Google Patents
Phenyltetrazole compounds Download PDFInfo
- Publication number
- US20080119657A1 US20080119657A1 US12/021,313 US2131308A US2008119657A1 US 20080119657 A1 US20080119657 A1 US 20080119657A1 US 2131308 A US2131308 A US 2131308A US 2008119657 A1 US2008119657 A1 US 2008119657A1
- Authority
- US
- United States
- Prior art keywords
- compound according
- compound
- solvent
- acid
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VSIJDLABUOWKBT-UHFFFAOYSA-N CCCC1=NC(C(C)(C)O)=C(C(=O)O)N1C.CCCCC(=O)N(C)C(C(=O)O)C(C)C.CCCCC1=NC(Cl)=C(CO)N1C.CCCCC1=NC2(CCCC2)C(=O)N1C.CCOC1=NC2=CC=CC(C(=O)O)=C2N1C Chemical compound CCCC1=NC(C(C)(C)O)=C(C(=O)O)N1C.CCCCC(=O)N(C)C(C(=O)O)C(C)C.CCCCC1=NC(Cl)=C(CO)N1C.CCCCC1=NC2(CCCC2)C(=O)N1C.CCOC1=NC2=CC=CC(C(=O)O)=C2N1C VSIJDLABUOWKBT-UHFFFAOYSA-N 0.000 description 4
- IQJPCZGGQJRKKU-UHFFFAOYSA-N CCC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1.CP Chemical compound CCC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1.CP IQJPCZGGQJRKKU-UHFFFAOYSA-N 0.000 description 3
- LPVIQDKDYYVSIR-UHFFFAOYSA-N CC1=C(C2=NNN=N2)C=CC=C1.CP Chemical compound CC1=C(C2=NNN=N2)C=CC=C1.CP LPVIQDKDYYVSIR-UHFFFAOYSA-N 0.000 description 1
- RSGAJCQSHABQJF-UHFFFAOYSA-N CCC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1 Chemical compound CCC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1 RSGAJCQSHABQJF-UHFFFAOYSA-N 0.000 description 1
- AZWMXNDUEBPVPD-UHFFFAOYSA-N CCC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1.CCC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1.CP.CP.II.I[IH]I.[H]C Chemical compound CCC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1.CCC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1.CP.CP.II.I[IH]I.[H]C AZWMXNDUEBPVPD-UHFFFAOYSA-N 0.000 description 1
- DAFMHQNTICWCTM-UHFFFAOYSA-N CCC1=CC=C([Y])C=C1 Chemical compound CCC1=CC=C([Y])C=C1 DAFMHQNTICWCTM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Definitions
- the present invention relates to novel substituted phenyltetrazole compounds useful as intermediates in the preparation of angiotensin II antagonists, and a process for the conversion thereof to said molecules.
- Angiotensin II antagonists are medicaments useful in the treatment of hypertension, anxiety, glaucoma and cardiac attacks.
- a number of these compounds share a biphenyltetrazole moiety and can be represented by the following formula (I)
- Z is an optionally substituted heterocycle containing at least one nitrogen atom; or an open amide residue.
- substituent Z can have the following meanings
- angiotensin II antagonists (a) [2-butyl-4-chloro-5-hydroxymethyl-imidazol-1-yl]losartan; (b) [2-ethoxy-3H-benzimidazole-4-carboxylic acid] candesartan; (c) [2-butyl-1,3-diaza-spiro[4,4]non-1-en-4-on-3-yl]irbesartan; (d) [(S)—N-(1-carboxy-2-methylprop-1-yl)-N-pentanoylamino]valsartan; and (e) [5-carboxy-4-(1-hydroxy-1-methylethyl)-2-propy-imidazo-1-yl]olmesartan.
- losartan can be prepared by reaction between a compound of formula (III)
- X is a leaving group and P is a tetrazole protecting group, and a base Z 1 -H, wherein Z 1 has the meaning as indicated in (a); the subsequent removal of the protecting group P affords losartan.
- WO93/10106 discloses the preparation of losartan by cross coupling reaction between a compound of formula (IV)
- Z 1 has the meaning as indicated in (a) above, Y is a leaving group such as halogen, methanesulfonyloxy, fluorosulfonyloxy or trifluoromethanesulfonyloxy; and a synthon of formula (V)
- Candesartan, irbesartan, valsartan, and olmesartan can be obtained analogously.
- a protecting group is a group which blocks a reactive site in a compound having more than one reactive group, so that the chemical reaction can be carried out selectively on another unprotected reactive site, said protecting group being easily removed at the end of the selective reaction.
- the compounds of formula (II), (III) and (V) reported above contain a tetrazol-5-yl group, in which a reactive nitrogen atom is present. It is known that the reactive tetrazole nitrogen in a compound of formula (II), (III) and (V) can be protected with a group such as triphenylmethyl, p-nitrophenyl, pyridyl or pyrimidyl. Analogously, the 1-methyl-1-phenylethyl group would be a very good protecting group for the reactive tetrazole nitrogen, in that it is particularly resistant to cleavage during the selective reaction, but it also is resistant to cleavage after completion of the reaction.
- U.S. Pat. No. 5,412,102 discloses the use of the 1-methyl-1-phenylethyl group (cumyl) as a protecting group in the preparation of 1-butyl-2-[2′-(2H-tetrazol-5-yl)biphenyl-4-yl-methyl]-1H-indole-3-carboxylic acid.
- the deprotection is carried out by reaction with about 3-4 equivalents of a Lewis acid, preferably boron trifluoride etherate (see example 15), in the presence of a thiol, an arylthiol, a 2-mercaptoacetic acid, preferably a 2-mercaptoacetate, or pentaerythritol tetrakis(2-mercaptoacetate).
- a Lewis acid preferably boron trifluoride etherate (see example 15)
- a first aspect of the invention is a process for deprotecting the reactive tetrazole nitrogen in a compound containing a 2-(1-methyl-1-phenylethyl)-2H-tetrazolyl group, comprising the reaction of said protected compound with an anhydrous hydrohalic acid or with an aqueous solution thereof at a concentration higher than 20% weight/weight.
- a compound containing a 2-(1-methyl-1-phenylethyl)-2H-tetrazolyl group is preferably a compound of formula (VI)
- P is a 1-methyl-1-phenylethyl group
- Z has one of the following meanings (a), (b), (c), (d), or (e)
- a hydrohalic acid preferably is an acid selected from the group consisting of hydrochloric acid and hydrobromic acid.
- the reaction can be carried out in an organic protic or aprotic solvent.
- An organic protic solvent may be a C 1 -C 4 alkanol, such as methanol, ethanol, isopropanol or butanol.
- An organic aprotic solvent may be an ether, such as tetrahydrofuran or dioxane; an ester, such as ethyl acetate, butyl acetate or isopropyl acetate; a hydrocarbon, such as toluene; a chlorinated solvent, such as dichloromethane, dichloroethane or chlorobenzene; a keton, such as acetone; or a nitrile, such as acetonitrile.
- Hydrochloric acid is typically used in aqueous solution or as a gas (anhydrous) in an organic protic or aprotic solvent; hydrobromic acid is typically used in aqueous solution.
- the reaction is preferably carried out using hydrochloric acid in aqueous solution at a concentration equal to or higher than 30% w/w, more preferably equal to or higher than 35%, or anhydrous hydrochloric acid (gas) in dichloromethane or ethyl acetate solution.
- Hydrobromic acid is typically used at a concentration equal to or higher than 35% w/w, preferably equal to or higher than 40%.
- the amount of hydrohalic acid used ranges from 1.1 moles to 5 moles, compared with the substrate to be deprotected, preferably from 2 to 3 moles.
- the reaction can be carried out at a temperature ranging from 0° C. to the reflux temperature of the solvent mixture, preferably from 15° C. to 70° C.
- an organic protic or aprotic solvent as defined above, preferably toluene, in homogeneous or heterogeneous mixture with water, can be used as co-solvent.
- a further aspect of the invention is a process for the preparation of losartan, valsartan, irbesartan, candesartan, and olmesartan comprising the removal of the 1-methyl-1-phenylethyl protecting group in a compound of formula (VI),
- the compounds of formula (VI) reported above, as well as the isomers and tautomers thereof, are novel compounds and are a further object of the invention. They can be prepared according to the procedures mentioned in EP 253310 and WO 93/10106. In particular, the reactive tetrazole nitrogen can be protected with a 1-methyl-1-phenylethyl group as described in example 2 of U.S. Pat. No. 5,412,102.
- the aqueous phase is poured into a solution of 125 g of sodium acetate in water, the formed precipitate is filtered, thoroughly washed with water and dried under vacuum at 70° C., thereby obtaining 77 g of irbesartan.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Novel phenyltetrazole compounds useful as intermediates in the preparation of angiotensin II antagonists and the processes for the conversion thereof to biologically active molecules.
Description
- The present invention relates to novel substituted phenyltetrazole compounds useful as intermediates in the preparation of angiotensin II antagonists, and a process for the conversion thereof to said molecules.
-
- wherein Z is an optionally substituted heterocycle containing at least one nitrogen atom; or an open amide residue.
-
- which identify specific angiotensin II antagonists: (a) [2-butyl-4-chloro-5-hydroxymethyl-imidazol-1-yl]losartan; (b) [2-ethoxy-3H-benzimidazole-4-carboxylic acid] candesartan; (c) [2-butyl-1,3-diaza-spiro[4,4]non-1-en-4-on-3-yl]irbesartan; (d) [(S)—N-(1-carboxy-2-methylprop-1-yl)-N-pentanoylamino]valsartan; and (e) [5-carboxy-4-(1-hydroxy-1-methylethyl)-2-propy-imidazo-1-yl]olmesartan.
-
- wherein X is a leaving group and P is a tetrazole protecting group, and a base Z1-H, wherein Z1 has the meaning as indicated in (a); the subsequent removal of the protecting group P affords losartan.
-
-
- wherein —B(R1R2) is a disubstituted boron atom and P is a tetrazole protecting group, to obtain the compound of formula (II) reported above, and subsequent removal of the protecting group P.
- Candesartan, irbesartan, valsartan, and olmesartan can be obtained analogously.
- Generally speaking, a protecting group is a group which blocks a reactive site in a compound having more than one reactive group, so that the chemical reaction can be carried out selectively on another unprotected reactive site, said protecting group being easily removed at the end of the selective reaction.
- The compounds of formula (II), (III) and (V) reported above contain a tetrazol-5-yl group, in which a reactive nitrogen atom is present. It is known that the reactive tetrazole nitrogen in a compound of formula (II), (III) and (V) can be protected with a group such as triphenylmethyl, p-nitrophenyl, pyridyl or pyrimidyl. Analogously, the 1-methyl-1-phenylethyl group would be a very good protecting group for the reactive tetrazole nitrogen, in that it is particularly resistant to cleavage during the selective reaction, but it also is resistant to cleavage after completion of the reaction.
- U.S. Pat. No. 5,412,102 discloses the use of the 1-methyl-1-phenylethyl group (cumyl) as a protecting group in the preparation of 1-butyl-2-[2′-(2H-tetrazol-5-yl)biphenyl-4-yl-methyl]-1H-indole-3-carboxylic acid. The deprotection is carried out by reaction with about 3-4 equivalents of a Lewis acid, preferably boron trifluoride etherate (see example 15), in the presence of a thiol, an arylthiol, a 2-mercaptoacetic acid, preferably a 2-mercaptoacetate, or pentaerythritol tetrakis(2-mercaptoacetate).
- The removal of the cumyl protecting group is efficient, but the reagents used do not fulfil the requirements for the production on an industrial scale. Boron trifluoride etherate is in fact a dangerous, flammable compound (Bretherick, Handbook of reactive chemical hazards, IV ed. page 481). Similarly, thiols and the derivatives thereof are remarkably difficult to use. There is therefore the need for of a novel process which allows to remove the 1-methyl-1-phenylethyl group from the phenyltetrazole derivatives, overcoming the mentioned problems.
- An efficient method for removing the reactive tetrazole nitrogen 1-methyl-1-phenylethyl protecting group has been found. Said method is particularly useful in the preparation of losartan, valsartan, irbesartan, candesartan, and olmesartan, using the novel intermediates thereof in which the reactive tetrazole nitrogen is protected by said 1-methyl-1-phenylethyl group.
- A first aspect of the invention is a process for deprotecting the reactive tetrazole nitrogen in a compound containing a 2-(1-methyl-1-phenylethyl)-2H-tetrazolyl group, comprising the reaction of said protected compound with an anhydrous hydrohalic acid or with an aqueous solution thereof at a concentration higher than 20% weight/weight.
-
-
- A hydrohalic acid preferably is an acid selected from the group consisting of hydrochloric acid and hydrobromic acid.
- When the hydrohalic acid is used in the anhydrous form (gas), the reaction can be carried out in an organic protic or aprotic solvent.
- An organic protic solvent may be a C1-C4 alkanol, such as methanol, ethanol, isopropanol or butanol. An organic aprotic solvent may be an ether, such as tetrahydrofuran or dioxane; an ester, such as ethyl acetate, butyl acetate or isopropyl acetate; a hydrocarbon, such as toluene; a chlorinated solvent, such as dichloromethane, dichloroethane or chlorobenzene; a keton, such as acetone; or a nitrile, such as acetonitrile.
- Hydrochloric acid is typically used in aqueous solution or as a gas (anhydrous) in an organic protic or aprotic solvent; hydrobromic acid is typically used in aqueous solution.
- The reaction is preferably carried out using hydrochloric acid in aqueous solution at a concentration equal to or higher than 30% w/w, more preferably equal to or higher than 35%, or anhydrous hydrochloric acid (gas) in dichloromethane or ethyl acetate solution.
- Hydrobromic acid is typically used at a concentration equal to or higher than 35% w/w, preferably equal to or higher than 40%.
- The amount of hydrohalic acid used ranges from 1.1 moles to 5 moles, compared with the substrate to be deprotected, preferably from 2 to 3 moles.
- The reaction can be carried out at a temperature ranging from 0° C. to the reflux temperature of the solvent mixture, preferably from 15° C. to 70° C.
- When the reaction is carried out with a hydrohalic acid aqueous solution, an organic protic or aprotic solvent, as defined above, preferably toluene, in homogeneous or heterogeneous mixture with water, can be used as co-solvent.
-
-
- by reacting a compound of formula (VI) with an anhydrous hydrohalic acid or an aqueous solution thereof at a concentration above 20% w/w.
- The compounds of formula (VI) reported above, as well as the isomers and tautomers thereof, are novel compounds and are a further object of the invention. They can be prepared according to the procedures mentioned in EP 253310 and WO 93/10106. In particular, the reactive tetrazole nitrogen can be protected with a 1-methyl-1-phenylethyl group as described in example 2 of U.S. Pat. No. 5,412,102.
- The following examples illustrate the invention.
- A suspension of [2′-(1-methyl-1-phenyl-ethyl)]-2H-tetrazol-5-yl]phenyl boronic acid (26.7 mmoles, 8.3 g) in diethoxymethane is added under stirring with two portions of water (0.55 ml, 31 mmoles) at room temperature, in about 1 hour. After completion of the addition, potassium carbonate (8.6 g, 62 mmoles), [3-(4-bromo-benzyl)-2-butyl-5-chloro-3H-imidazol-4-yl]-methanol (8.97 g, 25 mmoles), triphenylphosphine (262 mg, 1.0 mmoles), palladium acetate (56 mg, 0.25 mmoles) and THF (20 ml) are added. The mixture is refluxed for 6 hours, then the aqueous phase is discarded. The organic phase is washed with 30 ml of water, concentrated to dryness and the resulting product is crystallized from isopropanol, thereby obtaining 10.6 g of (2-butyl-5-chloro-3-{2′-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-biphenyl-4-ylmethyl}-3H-imidazol-4-yl)-methanol.
- NMR: (1H, DMSO, 300 mHz): d 0.79 (3H, t, J=8, CH3), 1.20 (2H, sext, J=8, CH3CH2), 1.42 (2H, quin, J=8, CH3CH2CH2), 1.91 (6H, s, CMe2), 2.41 (2H, t, J=8, CH3CH2CH2CH2), 4.30 (2H, d, J=3, CH2OH), 5.15-5.20 (3H, m, CH2Ar and OH), 6.88-7.0 (4H, m, ArH), 7.08 (2H, d, J=8, ArH), 7.22-7.29 (3H, m, ArH), 7.41-7.62 (3H, m, ArH), 7.88 (1H, d, J=7, ArH).
- (13C, DMSO, 300 mHz): d 14.3, 22.32, 26.5, 29.2, 29.6, 47.1, 52.1, 68.8, 125.1, 126.0, 126.3, 126.5, 126.7, 128.3, 128.5, 129.2, 129.9, 130.1, 131.0, 131.2, 136.4, 140.1, 141.7, 144.6, 147.9, 164.6.
- The following compounds can be prepared analogously:
- 2-butyl-3-{2′-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-biphenyl-4-ylmethyl}-1,3-diaza-spiro[4.4]non-1-en-4-one;
- (S)—N-(1-oxopentyl)-N-[[2′-[(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl][1,1′-biphenyl]-4-yl]methyl]-valine;
- 2-ethoxy-3-{2′-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-biphenyl-4-ylmethyl}-3H-benzoimidazole-4-carboxylic acid; and
- (1H-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-[[2′-[2-(1-methyl-1-fenylethyl)-1H-tetrazol-5-yl) [1,1′-biphenyl]-4-yl]methyl)
- 10 g (0.02 moles) of (2-butyl-5-chloro-3-{2′-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-biphenyl-4-ylmethyl}-3H-imidazol-4-yl)-methanol are dissolved in 50 ml of 37% aqueous hydrochloric acid under stirring at a temperature of 15-20° C. The mixture is stirred for a further 4 h, then washed 3 times with 25 ml of toluene. The aqueous phase is poured into a solution of 55 g of sodium acetate in water, the formed precipitate is filtered, thoroughly washed with water and dried under vacuum at 70° C., thereby obtaining 8 g of losartan.
- NMR: 1H (DMSO, 300 mHz): d 0.80 (3H, t, J=10, CH3), 1.25 (2H, sest, J=10, CH3CH2), 1.45 (2H, quin, J=10, CH3CH2CH2), 2.45-2.55 (2H, m, CH3CH2CH2CH2), 4.30 (2H, 2H, CH2OH), 5.30 (2H, s, CH2Ar), 7.10 (4H, s, ArH), 7.45-7.70 (4H, m, ArH).
- Operating analogously, from the respective intermediates of formula (VI) obtainable according to Example 1, the following compounds: valsartan, irbesartan, candesartan and olmesartan can be obtained.
- 10 g (0.02 moles) of (2-butyl-5-chloro-3-{2′-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-biphenyl-4-ylmethyl}-3H-imidazol-4-yl)-methanol are dissolved in 50 ml of dichloromethane and gaseous HCl is bubbled at a temperature of 0-10° C. After 2 h the reaction mixture is poured into a solution of 55 g of sodium acetate in water, the formed precipitate is filtered, thoroughly washed with water and dried under vacuum at 70° C., thereby obtaining 7.8 g of losartan.
- Operating analogously, from the respective intermediates of formula (VI) obtainable according to Example 1, the following compounds: valsartan, irbesartan, candesartan and olmesartan can be obtained.
- 10 g (0.02 moles) of (2-butyl-5-chloro-3-{2′-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-biphenyl-4-ylmethyl}-3H-imidazol-4-yl)-methanol are dissolved in 50 ml of 40% aqueous hydrobromic acid under stirring at a temperature of 15-20° C. The mixture is stirred for a further 4 h, then washed 3 times with 25 ml of toluene. The aqueous phase is poured into a solution of 55 g of sodium acetate in water, the formed precipitate is filtered, thoroughly washed with water and dried under vacuum at 70° C., thereby obtaining 7.8 g of losartan.
- Operating analogously, from the respective intermediates of formula (VI) obtainable according to Example 1, the following compounds: valsaltan, irbesartan, candesartan and olmesartan can be obtained.
- 124 g (0.228 moles) of 2-butyl-3-{2′-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-biphenyl-4-ylmethyl}-1,3-diaza-spiro[4.4]non-1-en-4-one are dissolved in 500 ml of toluene and 900 ml of 37% aqueous hydrochloric acid are added thereto under stirring at a temperature of 15-20° C. The mixture is stirred for a further 4 h, then the aqueous phase is separated and washed twice with 250 ml of toluene. The aqueous phase is poured into a solution of 125 g of sodium acetate in water, the formed precipitate is filtered, thoroughly washed with water and dried under vacuum at 70° C., thereby obtaining 77 g of irbesartan.
- NMR: 1H (DMSO, 300 mHz): d 0.80 (3H, t); 1.26-(2H, m), 1.46 (2H, m); 1.65-1.84 (8H, m); 2.29 (2H, t); 4.67 (2H, s); 7.08 (4H, s); 7.60 (4H, m).
- Operating analogously, from the respective intermediates of formula (VI) obtainable according to Example 1, the following compounds: valsartan, losartan, candesartan and olmesartan can be obtained.
Claims (19)
2. The compound of claim 1 provided by a process for the deprotection of the reactive tetrazole nitrogen in a compound containing a 2-(1-methyl-1-phenylethyl)-2H-tetrazolyl group, comprising the reaction of the protected compound with an anhydrous hydrohalic acid or an aqueous solution thereof at a concentration higher than 20% w/w.
3. The compound according to claim 2 , wherein the acid is selected from the group consisting of hydrochloric acid and hydrobromic acid.
4. The compound according to claim 3 , wherein the amount of acid used ranges from 1.1 moles to 5 moles, compared with the substrate to be deprotected.
5. The compound according to claim 3 , wherein the hydrochloric acid aqueous solution has concentration equal to or higher than 30% w/w.
6. The compound according to claim 3 , wherein the hydrobromic acid aqueous solution has concentration equal to or higher than 35% w/w.
7. The compound according to claim 2 , wherein the reaction is carried out with an anhydrous hydrohalogen acid in an organic protic or aprotic solvent.
8. The compound according to claim 7 , wherein the solvent is selected from a C1-C4 alkanol; an ether; an ester; a hydrocarbon; a chlorinated solvent; a keton or a nitrile.
9. The compound according to claim 8 , wherein the reaction is carried out in dichloromethane or ethyl acetate.
10. The compound according to claim 2 , wherein an organic protic or aprotic solvent, in homogeneous or heterogeneous mixture with water, is used as co-solvent.
11. The compound according to claim 10 , wherein said solvent is toluene.
12. The compound according to claim 4 , wherein the hydrochloric acid aqueous solution has concentration equal to or higher than 30% w/w.
13. The compound according to claim 4 , wherein the hydrobromic acid aqueous solution has concentration equal to or higher than 35% w/w.
14. The compound according to claim 3 , wherein the reaction is carried out with an anhydrous hydrohalogen acid in an organic protic or aprotic solvent.
15. The compound according to claim 4 , wherein the reaction is carried out with an anhydrous hydrohalogen acid in an organic protic or aprotic solvent.
16. The compound according to claim 5 , wherein an organic protic or aprotic solvent, in homogeneous or heterogeneous mixture with water, is used as co-solvent.
17. The compound according to claim 6 , wherein an organic protic or aprotic solvent, in homogeneous or heterogeneous mixture with water, is used as co-solvent.
18. An isomer of the compound of claim 1 .
19. A tautomer of the compound of claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/021,313 US20080119657A1 (en) | 2003-11-28 | 2008-01-29 | Phenyltetrazole compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2003A002338 | 2003-11-28 | ||
IT002338A ITMI20032338A1 (en) | 2003-11-28 | 2003-11-28 | PHENYLTETRAZOLIC COMPOUNDS. |
US10/995,135 US7345072B2 (en) | 2003-11-28 | 2004-11-24 | Phenyltetrazole compounds |
US12/021,313 US20080119657A1 (en) | 2003-11-28 | 2008-01-29 | Phenyltetrazole compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/995,135 Division US7345072B2 (en) | 2003-11-28 | 2004-11-24 | Phenyltetrazole compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080119657A1 true US20080119657A1 (en) | 2008-05-22 |
Family
ID=34611237
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/995,135 Expired - Fee Related US7345072B2 (en) | 2003-11-28 | 2004-11-24 | Phenyltetrazole compounds |
US12/021,313 Abandoned US20080119657A1 (en) | 2003-11-28 | 2008-01-29 | Phenyltetrazole compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/995,135 Expired - Fee Related US7345072B2 (en) | 2003-11-28 | 2004-11-24 | Phenyltetrazole compounds |
Country Status (9)
Country | Link |
---|---|
US (2) | US7345072B2 (en) |
EP (1) | EP1555260B1 (en) |
JP (1) | JP2005162751A (en) |
AT (1) | ATE373645T1 (en) |
DE (1) | DE602004009030T2 (en) |
ES (1) | ES2273617T3 (en) |
IT (1) | ITMI20032338A1 (en) |
PL (1) | PL1555260T3 (en) |
PT (1) | PT1555260E (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101117128B1 (en) | 2009-06-02 | 2012-03-14 | 한국화학연구원 | Pharmaceutical composition for the prevention or treatment of osteoporosis or obesity comprising a phenyltetrazole derivative or a pharmaceutically acceptable salt thereof as an active ingredient |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2573800A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries Ltd. | Preparation of olmesartan medoxomil |
DE102004060699A1 (en) * | 2004-12-16 | 2006-06-22 | Ratiopharm Gmbh | Process for the preparation of candesartan |
WO2006067216A2 (en) * | 2004-12-22 | 2006-06-29 | Enantia, S. L. | Intermediate compounds for the preparation of an angiotensin ii receptor and process for the preparation of valsartan |
US7563814B2 (en) | 2005-01-03 | 2009-07-21 | Teva Pharmaceutical Industries Ltd. | Olmesartan medoxomil with reduced levels of impurities |
EP1812411A2 (en) * | 2005-07-05 | 2007-08-01 | Teva Pharmaceutical Industries Ltd. | Process for preparing valsartan |
EP1816131A1 (en) * | 2006-02-06 | 2007-08-08 | KRKA, tovarna zdravil, d.d., Novo mesto | Process for the preparation of olmesartan medoxomil |
EP1910343B1 (en) * | 2005-07-29 | 2014-10-29 | Krka | Process for the preparation of olmesartan medoxomil |
WO2007071750A1 (en) * | 2005-12-22 | 2007-06-28 | Enantia, S.L. | Intermediates and processes for the preparation of valsartan |
ES2300175B1 (en) * | 2006-02-14 | 2009-06-08 | Inke, S.A. | PROCEDURE FOR OBTAINING USEFUL INTERMEDIATES IN OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND. |
ITMI20061848A1 (en) * | 2006-09-27 | 2008-03-28 | Dipharma Spa | PROCEDURE FOR THE PREPARATION OF PHENYLTETRAZOLIC COMPOUNDS |
WO2009019303A2 (en) * | 2007-08-08 | 2009-02-12 | Lek Pharmaceuticals D.D. | A process for the preparation or purification of olmesartan medoxomil |
US20120184750A1 (en) | 2009-05-20 | 2012-07-19 | Ranbaxy Laboratories Limited | Process for the preparation of olmesartan medoxomil |
WO2011080684A1 (en) | 2009-12-31 | 2011-07-07 | Ranbaxy Laboratories Limited | Process for the preparation of candesartan cilexetil |
WO2011092666A1 (en) | 2010-01-29 | 2011-08-04 | Ranbaxy Laboratories Limited | An improved process for the preparation of candesartan cilexetil, polymorphic forms of n-trityl candesartan and their uses thereof |
CN102675294A (en) * | 2012-05-17 | 2012-09-19 | 浙江天宇药业股份有限公司 | Method of synthesizing losartan and losartan intermediates |
CN105001209A (en) * | 2015-06-29 | 2015-10-28 | 千辉药业(安徽)有限责任公司 | Synthetic method of irbesartan |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6264914B1 (en) * | 1996-10-28 | 2001-07-24 | Nycomed Imaging As | Contrast agents |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5412102A (en) * | 1994-05-27 | 1995-05-02 | Syntex (U.S.A.) Inc. | Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid |
TW409125B (en) * | 1996-04-22 | 2000-10-21 | Novartis Ag | Antivirally active heterocyclic azahexane derivatives |
JP2002145770A (en) * | 2000-08-30 | 2002-05-22 | Sankyo Co Ltd | Pharmaceutical composition for prophylaxis or treatment of cardiac insufficiency |
-
2003
- 2003-11-28 IT IT002338A patent/ITMI20032338A1/en unknown
-
2004
- 2004-11-19 AT AT04027599T patent/ATE373645T1/en active
- 2004-11-19 DE DE602004009030T patent/DE602004009030T2/en active Active
- 2004-11-19 PL PL04027599T patent/PL1555260T3/en unknown
- 2004-11-19 ES ES04027599T patent/ES2273617T3/en active Active
- 2004-11-19 PT PT04027599T patent/PT1555260E/en unknown
- 2004-11-19 EP EP04027599A patent/EP1555260B1/en not_active Not-in-force
- 2004-11-24 US US10/995,135 patent/US7345072B2/en not_active Expired - Fee Related
- 2004-11-25 JP JP2004340068A patent/JP2005162751A/en active Pending
-
2008
- 2008-01-29 US US12/021,313 patent/US20080119657A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6264914B1 (en) * | 1996-10-28 | 2001-07-24 | Nycomed Imaging As | Contrast agents |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101117128B1 (en) | 2009-06-02 | 2012-03-14 | 한국화학연구원 | Pharmaceutical composition for the prevention or treatment of osteoporosis or obesity comprising a phenyltetrazole derivative or a pharmaceutically acceptable salt thereof as an active ingredient |
Also Published As
Publication number | Publication date |
---|---|
PT1555260E (en) | 2007-12-04 |
EP1555260A1 (en) | 2005-07-20 |
ITMI20032338A1 (en) | 2005-05-29 |
ES2273617T3 (en) | 2008-03-16 |
PL1555260T3 (en) | 2008-02-29 |
US20050119488A1 (en) | 2005-06-02 |
US7345072B2 (en) | 2008-03-18 |
JP2005162751A (en) | 2005-06-23 |
DE602004009030D1 (en) | 2007-10-31 |
ATE373645T1 (en) | 2007-10-15 |
DE602004009030T2 (en) | 2008-06-12 |
EP1555260B1 (en) | 2007-09-19 |
ES2273617T1 (en) | 2007-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080119657A1 (en) | Phenyltetrazole compounds | |
US8592474B2 (en) | Process for the preparation or purification of olmesartan medoxomil | |
KR20050057529A (en) | Process for the manufacture of valsartan | |
EP1777224A2 (en) | A process for the preparation of angiotensin II antagonistic compounds | |
US20080076932A1 (en) | A process for the preparation of phenyltetrazole compounds | |
US7868180B2 (en) | Process for the preparation of sartan derivatives and intermediates useful in such process | |
WO2001081336A8 (en) | Process for the synthesis of a known tetrazol derivative | |
SI21965A (en) | Preparation of tetrazole derivative | |
WO2007119246A2 (en) | An improved process for the manufacture of losartan potassium | |
US7385062B2 (en) | Process for the preparation of phenyltetrazole derivatives | |
EP0964861B1 (en) | Process for the production of tetrazolylbenzopyrans | |
US7964749B2 (en) | Process for obtaining valine derivatives useful for obtaining a pharmaceutically active compound | |
EP1741711A1 (en) | A process for the preparation of losartan derivatives by chlorination and reduction of the respective 1H-imidazole-5-carbaldehydes | |
US20080281097A1 (en) | Process for Preparing an Angiotensin II Receptor Antagonist | |
US7164029B2 (en) | Process for the preparation of benzylimidazole derivatives | |
KR20070117381A (en) | Novel process for the preparation of losartan | |
JPH07304773A (en) | Production of tetrazole compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DIPHARMA S.P.A., ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAZZETTI, GABRIELE;MAGRONE, DOMENICO;ERCOLI, MAURO;REEL/FRAME:020427/0185;SIGNING DATES FROM 20041021 TO 20041022 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |